TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Galmed Pharmaceuticals ( (GLMD) ) has shared an update.
Galmed Pharmaceuticals announced on November 17, 2025, the top-line results of their oncology mechanism of action studies involving a three-drug combination of Aramchol, Stivarga®, and Metformin, which demonstrated significant enhancement in killing gastrointestinal tumor cells both in vivo and in vitro. This combination has the potential to serve as a new fixed-dose treatment and a life-cycle IP strategy for Bayer’s Stivarga® as its patents near expiration, with plans to enter Phase 1b clinical trials in early 2026, potentially expanding Galmed’s pipeline and creating value for stakeholders.
Spark’s Take on GLMD Stock
According to Spark, TipRanks’ AI Analyst, GLMD is a Underperform.
Galmed Pharmaceuticals faces significant financial challenges, with no revenue and continuous losses, which heavily impact its stock score. Poor technical indicators and negative valuation metrics further weigh down the score. The strong equity position offers some support but is overshadowed by the lack of operational efficiency and profitability.
To see Spark’s full report on GLMD stock, click here.
More about Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on developing Aramchol for liver, cardiometabolic diseases, and gastrointestinal oncological therapeutics. The company is expanding its product pipeline to include oncological indications beyond NASH and fibrosis, targeting cardiometabolic conditions and other innovative drug candidates.
Average Trading Volume: 118,373
Technical Sentiment Signal: Strong Sell
Current Market Cap: $5.7M
For detailed information about GLMD stock, go to TipRanks’ Stock Analysis page.